CA2931413A1 - Measurement and uses of oxidative status - Google Patents
Measurement and uses of oxidative status Download PDFInfo
- Publication number
- CA2931413A1 CA2931413A1 CA2931413A CA2931413A CA2931413A1 CA 2931413 A1 CA2931413 A1 CA 2931413A1 CA 2931413 A CA2931413 A CA 2931413A CA 2931413 A CA2931413 A CA 2931413A CA 2931413 A1 CA2931413 A1 CA 2931413A1
- Authority
- CA
- Canada
- Prior art keywords
- orp
- patient
- patients
- plasma
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000005259 measurement Methods 0.000 title description 28
- 230000001590 oxidative effect Effects 0.000 title description 23
- 238000000034 method Methods 0.000 claims description 42
- 238000012544 monitoring process Methods 0.000 claims description 38
- 239000010836 blood and blood product Substances 0.000 claims description 37
- 229940125691 blood product Drugs 0.000 claims description 37
- 230000033116 oxidation-reduction process Effects 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 238000003860 storage Methods 0.000 claims description 6
- 210000003743 erythrocyte Anatomy 0.000 claims description 5
- 238000012360 testing method Methods 0.000 abstract description 10
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 239000012491 analyte Substances 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 238000000840 electrochemical analysis Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 56
- 230000036542 oxidative stress Effects 0.000 description 45
- 238000011282 treatment Methods 0.000 description 45
- 210000001124 body fluid Anatomy 0.000 description 44
- 239000010839 body fluid Substances 0.000 description 44
- 208000014674 injury Diseases 0.000 description 37
- 208000028399 Critical Illness Diseases 0.000 description 33
- 210000001519 tissue Anatomy 0.000 description 29
- 208000010125 myocardial infarction Diseases 0.000 description 24
- 230000008733 trauma Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 17
- 238000011256 aggressive treatment Methods 0.000 description 15
- 230000006378 damage Effects 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 206010019196 Head injury Diseases 0.000 description 9
- 208000036142 Viral infection Diseases 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 9
- 239000007800 oxidant agent Substances 0.000 description 9
- 230000009385 viral infection Effects 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 208000007587 Transfusion-Related Acute Lung Injury Diseases 0.000 description 6
- 206010000891 acute myocardial infarction Diseases 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 238000009533 lab test Methods 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 230000003244 pro-oxidative effect Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 4
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 108010071690 Prealbumin Proteins 0.000 description 3
- 102000009190 Transthyretin Human genes 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 108010009043 arylesterase Proteins 0.000 description 2
- 102000028848 arylesterase Human genes 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000001425 electrospray ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 1
- 208000004221 Multiple Trauma Diseases 0.000 description 1
- 208000006670 Multiple fractures Diseases 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940021317 other blood product in atc Drugs 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- BDJXVNRFAQSMAA-UHFFFAOYSA-N quinhydrone Chemical class OC1=CC=C(O)C=C1.O=C1C=CC(=O)C=C1 BDJXVNRFAQSMAA-UHFFFAOYSA-N 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012883 sequential measurement Methods 0.000 description 1
- 101150017120 sod gene Proteins 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- -1 superoxide ion Chemical class 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Electrochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93892507P | 2007-05-18 | 2007-05-18 | |
| US60/938,925 | 2007-05-18 | ||
| CA2684144A CA2684144C (en) | 2007-05-18 | 2008-05-16 | Measurement and uses of oxidative status |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2684144A Division CA2684144C (en) | 2007-05-18 | 2008-05-16 | Measurement and uses of oxidative status |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2931413A1 true CA2931413A1 (en) | 2008-11-27 |
Family
ID=40122150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2931413A Abandoned CA2931413A1 (en) | 2007-05-18 | 2008-05-16 | Measurement and uses of oxidative status |
| CA2684144A Active CA2684144C (en) | 2007-05-18 | 2008-05-16 | Measurement and uses of oxidative status |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2684144A Active CA2684144C (en) | 2007-05-18 | 2008-05-16 | Measurement and uses of oxidative status |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9063070B2 (enExample) |
| EP (1) | EP2147303B1 (enExample) |
| JP (4) | JP5330381B2 (enExample) |
| CA (2) | CA2931413A1 (enExample) |
| ES (1) | ES2627188T3 (enExample) |
| WO (1) | WO2008144481A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627188T3 (es) | 2007-05-18 | 2017-07-27 | Aytu Bioscience, Inc. | Medición y usos del estado oxidativo |
| US8709709B2 (en) | 2007-05-18 | 2014-04-29 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
| KR20140034720A (ko) | 2011-02-28 | 2014-03-20 | 로익스 다이어그노스틱스, 아이엔씨. | 산화-환원 전위를 측정하기 위한 방법 및 장치 |
| RU2497107C2 (ru) * | 2012-01-24 | 2013-10-27 | Общество с ограниченной ответственностью "БИНАКОР-ХТ" | Способ измерения редокс потенциала биологических сред |
| EA201491808A1 (ru) | 2012-04-19 | 2015-03-31 | Луоксис Дайэгностикс, Инк. | Многослойный гель |
| CA2847665A1 (en) * | 2012-10-23 | 2014-04-23 | Raphael Bar-Or | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
| JP6142122B2 (ja) * | 2013-07-31 | 2017-06-07 | 慶孝 大友 | 唾液成分のｏｒｐ数値化判定測定装置の活用方法 |
| RU2560705C2 (ru) * | 2013-11-01 | 2015-08-20 | Государственное бюджетное учреждение здравоохранения города Москвы Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы | Способ мониторинга состояния пациента после трансплантации органа |
| WO2016169591A1 (en) * | 2015-04-22 | 2016-10-27 | Huawei Technologies Co., Ltd. | An audio signal processing apparatus and method |
| JP6251878B1 (ja) * | 2016-11-18 | 2017-12-27 | オルプ株式会社 | 酸化還元電位（ｏｒｐ）測定装置および利用方法 |
| JP6253171B1 (ja) * | 2017-07-25 | 2017-12-27 | 慶孝 大友 | Ｏｒｐ数値化判定装置および使用方法 |
| JP6454836B1 (ja) * | 2018-07-19 | 2019-01-16 | 慶孝 大友 | 唾液ｏｒｐ測定装置及び使用方法 |
| WO2024074617A1 (en) * | 2022-10-06 | 2024-04-11 | Institut National de la Santé et de la Recherche Médicale | Methods of diagnosing acute circulatory failure |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3956094A (en) * | 1974-03-29 | 1976-05-11 | Olin Corporation | Apparatus for monitoring available chlorine in swimming pools |
| US4225410A (en) * | 1978-12-04 | 1980-09-30 | Technicon Instruments Corporation | Integrated array of electrochemical sensors |
| US4299919A (en) * | 1980-06-30 | 1981-11-10 | St. Louis University | Perfusate redox potential controller |
| DE3278334D1 (en) * | 1981-10-23 | 1988-05-19 | Genetics Int Inc | Sensor for components of a liquid mixture |
| US4571292A (en) * | 1982-08-12 | 1986-02-18 | Case Western Reserve University | Apparatus for electrochemical measurements |
| US5682884A (en) * | 1983-05-05 | 1997-11-04 | Medisense, Inc. | Strip electrode with screen printing |
| US5260321A (en) * | 1984-11-12 | 1993-11-09 | Sandoz Ltd. | Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins |
| US4963245A (en) * | 1986-05-02 | 1990-10-16 | Ciba Corning Diagnostics Corp. | Unitary multiple electrode sensor |
| US4865717A (en) * | 1987-05-26 | 1989-09-12 | Transducer Research, Inc. | Electrochemical micro sensor |
| US5273639A (en) * | 1988-03-31 | 1993-12-28 | Agency Of Industrial Science & Technology | Probe electrode |
| JPH0752170B2 (ja) * | 1988-05-27 | 1995-06-05 | ダイキン工業株式会社 | 拡散制限膜保持具収容容器 |
| US5312590A (en) * | 1989-04-24 | 1994-05-17 | National University Of Singapore | Amperometric sensor for single and multicomponent analysis |
| JP2506312Y2 (ja) * | 1989-10-31 | 1996-08-07 | 豊田合成株式会社 | エレクトロクロミック素子 |
| CH681351A5 (enExample) * | 1990-04-12 | 1993-03-15 | Hans Baer Dr | |
| IE66038B1 (en) * | 1990-06-12 | 1995-12-13 | British Tech Group | Antioxidant assay |
| US5165406A (en) * | 1990-09-13 | 1992-11-24 | Via Medical Corporation | Electrochemical sensor apparatus and method |
| US5227307A (en) * | 1991-07-26 | 1993-07-13 | Diagnostic Markers, Inc. | Test for the rapid evaluation of ischemic state |
| US5387329A (en) * | 1993-04-09 | 1995-02-07 | Ciba Corning Diagnostics Corp. | Extended use planar sensors |
| EP0706581A4 (en) | 1993-04-30 | 1999-02-10 | Pacific Northwest Research Fou | DNA PROFILES INDICATORS OF CELLULAR OXYREDUCTION POTENTIAL AND CANCER RISK |
| GB9325189D0 (en) * | 1993-12-08 | 1994-02-09 | Unilever Plc | Methods and apparatus for electrochemical measurements |
| DE4404130A1 (de) * | 1994-02-09 | 1995-08-10 | Siemens Ag | Elektrochemische Bestimmung der Sauerstoffkonzentration |
| JPH09510899A (ja) * | 1994-03-30 | 1997-11-04 | ペースセッター アクチボラゲット | 血流速度測定装置 |
| US5672811A (en) * | 1994-04-21 | 1997-09-30 | Ngk Insulators, Ltd. | Method of measuring a gas component and sensing device for measuring the gas component |
| US5494562A (en) * | 1994-06-27 | 1996-02-27 | Ciba Corning Diagnostics Corp. | Electrochemical sensors |
| US5782879A (en) * | 1995-06-02 | 1998-07-21 | Sulzer Intermedics Inc. | Apparatus and method for discriminating flow of blood in a cardiovascular system |
| SE9504233D0 (sv) * | 1995-11-27 | 1995-11-27 | Pacesetter Ab | Implantable medical device |
| US5679532A (en) * | 1995-12-13 | 1997-10-21 | University Technology Corporation | Serum ferritin as a predictor of the acute respiratory distress syndrome |
| JP3117192B2 (ja) | 1996-04-09 | 2000-12-11 | 有限会社ホワイト | 酸化還元電位測定機能内蔵健康管理計 |
| SE9603569D0 (sv) * | 1996-09-30 | 1996-09-30 | Pacesetter Ab | Electrochemical sensor |
| US6269261B1 (en) * | 1996-10-26 | 2001-07-31 | Yugen Kaisha Endo Process | Health care instrument containing oxidation-reduction potential measuring function |
| US6369106B1 (en) * | 1996-12-26 | 2002-04-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds |
| ATE227844T1 (de) * | 1997-02-06 | 2002-11-15 | Therasense Inc | Kleinvolumiger sensor zur in-vitro bestimmung |
| NZ337954A (en) | 1997-03-13 | 2001-09-28 | First Opinion Corp | Computerized disease management method adjusts a disease therapy for a patient based on obtained health data |
| US6177260B1 (en) * | 1997-07-11 | 2001-01-23 | The Hong Kong Polytechnic University | Measurement of antioxidant (reducing) power and/or antioxidant concentration |
| JPH1183797A (ja) * | 1997-09-03 | 1999-03-26 | Yoshitaka Otomo | 生物用酸化還元電位測定装置 |
| US5906921A (en) * | 1997-09-29 | 1999-05-25 | Matsushita Electric Industrial Co., Ltd. | Biosensor and method for quantitative measurement of a substrate using the same |
| SE9703957D0 (sv) * | 1997-10-29 | 1997-10-29 | Pacesetter Ab | Method and device for sensing |
| SE9703958D0 (sv) * | 1997-10-29 | 1997-10-29 | Pacesetter Ab | Method and device for determination of concentration |
| US6429021B1 (en) * | 1998-03-19 | 2002-08-06 | Amway Corporation | Antioxidant activity profile assay |
| WO1999051974A1 (fr) * | 1998-04-02 | 1999-10-14 | Matsushita Electric Industrial Co., Ltd. | Procede de determination d'un substrat |
| US6262264B1 (en) * | 1998-06-01 | 2001-07-17 | Roche Diagnostics Corporation | Redox reversible imidazole osmium complex conjugates |
| DE59914983D1 (de) * | 1998-06-04 | 2009-04-30 | Sphere Medical Ltd | Kalibrierungsfluid für einen sensor zur messung eisfluids |
| JP3267936B2 (ja) * | 1998-08-26 | 2002-03-25 | 松下電器産業株式会社 | バイオセンサ |
| DE19846148C2 (de) * | 1998-10-01 | 2002-10-10 | Igor Popov | Verfahren zur Beurteilung der oxidativen Modifikation proteinhaltiger Stoffe mittels Messung ihrer antiradikalen Aktivität |
| US20050142613A1 (en) * | 1998-10-02 | 2005-06-30 | David Bar-Or | Test for the rapid evaluation of ischemic states and kits |
| JP4205792B2 (ja) * | 1998-12-04 | 2009-01-07 | 日本碍子株式会社 | ＮＯｘ分解電極及びＮＯｘ濃度測定装置 |
| CA2378678C (en) * | 1999-06-08 | 2009-08-04 | Broadley Technologies Corporation | Reference electrode having a microfluidic flowing liquid junction |
| US6616819B1 (en) * | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
| US20020115619A1 (en) * | 2000-10-04 | 2002-08-22 | Rubenstein Ronald C. | Compositions and methods for treatment of cystic fibrosis |
| JP4154884B2 (ja) | 2000-11-10 | 2008-09-24 | 慶孝 大友 | 酸化還元電位測定装置および方法 |
| CA2440592C (en) | 2001-03-12 | 2012-05-15 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Oxidation-reduction sensitive green fluorescent protein variants |
| US6793632B2 (en) * | 2001-06-12 | 2004-09-21 | Lifescan, Inc. | Percutaneous biological fluid constituent sampling and measurement devices and methods |
| FR2829579A1 (fr) | 2001-09-11 | 2003-03-14 | Endogenics | Procede pour evaluer l'etat biologique d'un patient |
| GB0124613D0 (en) * | 2001-10-12 | 2001-12-05 | Alpha Thames Ltd | System and method for separating fluids |
| JP2005510712A (ja) * | 2001-11-26 | 2005-04-21 | イスケミア・テクノロジーズ・インコーポレーテッド | 虚血の電気化学的検知 |
| US7132296B2 (en) | 2002-02-15 | 2006-11-07 | Medical Products Manufacturing, Llc | Method for assaying the antioxidant capacity of a sample |
| AU2002951886A0 (en) | 2002-10-08 | 2002-10-24 | The Western Australian Centre For Pathology And Medical Research | A method for measuring antioxident status |
| AU2003287735A1 (en) * | 2002-11-12 | 2004-06-03 | Argose, Inc. | Non-invasive measurement of analytes |
| GR1004535B (el) | 2003-01-27 | 2004-04-22 | Medicon Hellas A.E. | Αυτοματοποιημενη μεθοδος προσδιορισμου της ολικης αντιοξειδωτικης ικανοτητος (total antioxidant capacity -tac-), και της διορθωμενης ολικης αντιοξειδωτικης ικανοτητος (corr tac) σε βιολογικα υγρα καιεκχυλισματα τροφων και ποτων βασισμενη στην αναστολη οξειδωσεως της κροκινης |
| JP2004350861A (ja) * | 2003-05-28 | 2004-12-16 | Tanita Corp | 健康管理装置 |
| US7276382B2 (en) | 2003-10-02 | 2007-10-02 | Noboru Horiguchi | Blood testing method |
| KR101092350B1 (ko) * | 2003-10-31 | 2011-12-09 | 라이프스캔 스코트랜드 리미티드 | 2개의 다른 인가전위들을 이용한 전기화학 센서에서의 간섭감소 방법을 사용하는 계량기 |
| RU2241997C1 (ru) | 2003-11-18 | 2004-12-10 | Евсеев Максим Александрович | Способ определения окислительно-восстановительного потенциала стенки желудка и двенадцатиперстной кишки |
| US7459075B2 (en) | 2004-07-07 | 2008-12-02 | Disney Enterprises, Inc. | Process control oxidation |
| GR1005561B (el) | 2005-10-03 | 2007-06-15 | Γεωργιος Κολιακος | Μετρηση της ολικης αντιοξειδωτικης ικανοτητος σε υγρα και διαλυμματα με τη χρηση της 3,3',5,5'-τετραμεθυλοβενζιδινης (τμβ) |
| US20090134043A1 (en) | 2005-11-10 | 2009-05-28 | Kevin Ward | Non-biofouling, universal redox electrode and measurement system |
| EP1790356A1 (de) | 2005-11-24 | 2007-05-30 | Vifor (International) Ag | Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en) |
| EP1906178A1 (en) * | 2006-09-26 | 2008-04-02 | F.Hoffmann-La Roche Ag | Method for detecting erroneous measurement results obtained with ion-selective electrodes |
| US8709709B2 (en) | 2007-05-18 | 2014-04-29 | Luoxis Diagnostics, Inc. | Measurement and uses of oxidative status |
| ES2627188T3 (es) | 2007-05-18 | 2017-07-27 | Aytu Bioscience, Inc. | Medición y usos del estado oxidativo |
| KR20140034720A (ko) | 2011-02-28 | 2014-03-20 | 로익스 다이어그노스틱스, 아이엔씨. | 산화-환원 전위를 측정하기 위한 방법 및 장치 |
| CA2847665A1 (en) | 2012-10-23 | 2014-04-23 | Raphael Bar-Or | Methods and systems for measuring and using the oxidation-reduction potential of a biological sample |
-
2008
- 2008-05-16 ES ES08755661.9T patent/ES2627188T3/es active Active
- 2008-05-16 WO PCT/US2008/063855 patent/WO2008144481A1/en not_active Ceased
- 2008-05-16 CA CA2931413A patent/CA2931413A1/en not_active Abandoned
- 2008-05-16 EP EP08755661.9A patent/EP2147303B1/en active Active
- 2008-05-16 CA CA2684144A patent/CA2684144C/en active Active
- 2008-05-16 JP JP2010509472A patent/JP5330381B2/ja not_active Expired - Fee Related
- 2008-05-16 US US12/121,945 patent/US9063070B2/en active Active
-
2013
- 2013-06-05 JP JP2013118787A patent/JP2013178277A/ja active Pending
- 2013-09-03 US US14/016,889 patent/US9383331B2/en active Active
-
2014
- 2014-02-27 JP JP2014036847A patent/JP2014134545A/ja active Pending
-
2016
- 2016-03-17 JP JP2016053891A patent/JP2016118568A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9063070B2 (en) | 2015-06-23 |
| WO2008144481A1 (en) | 2008-11-27 |
| EP2147303A4 (en) | 2010-09-01 |
| JP2010528290A (ja) | 2010-08-19 |
| JP5330381B2 (ja) | 2013-10-30 |
| JP2013178277A (ja) | 2013-09-09 |
| JP2014134545A (ja) | 2014-07-24 |
| US20140004551A1 (en) | 2014-01-02 |
| ES2627188T3 (es) | 2017-07-27 |
| EP2147303B1 (en) | 2017-03-29 |
| EP2147303A1 (en) | 2010-01-27 |
| CA2684144A1 (en) | 2008-11-27 |
| US9383331B2 (en) | 2016-07-05 |
| JP2016118568A (ja) | 2016-06-30 |
| US20090004686A1 (en) | 2009-01-01 |
| CA2684144C (en) | 2018-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2684144C (en) | Measurement and uses of oxidative status | |
| US10036723B2 (en) | Measurement and uses of oxidative status | |
| Sejersted et al. | Formate concentrations in plasma from patients poisoned with methanol | |
| Dittmar et al. | Bioimpedance phase angle indicates catabolism in Type 2 diabetes | |
| Banne et al. | Reduced level of serum thiols in patients with a diagnosis of active disease | |
| Verde et al. | Use of N, N-dimethyl-p-phenylenediamine to evaluate the oxidative status of human plasma | |
| Gargiulo et al. | Metformin decreases platelet superoxide anion production in diabetic patients | |
| Nishimura et al. | Glycated albumin is low in obese, non-diabetic children | |
| Spanidis et al. | Assessment of oxidative stress in septic and obese patients using markers of oxidation-reduction potential | |
| Grigorieva et al. | Measurement of plasma hemoglobin peroxidase activity | |
| JP2016529515A5 (enExample) | ||
| Sepúlveda-Loyola et al. | NOVEL antioxidant and oxidant biomarkers related to sarcopenia in COPD | |
| Polson et al. | Optimization of a diagnostic platform for oxidation–reduction potential (ORP) measurement in human plasma | |
| ES2549860T3 (es) | Diagnóstico y pronóstico de estados patológicos relacionados con la dipepitidil peptidasa | |
| Tolan et al. | Analytical performance of three whole blood point-of-care lactate devices compared to plasma lactate comparison methods and a flow-injection mass spectrometry method | |
| Kopčil et al. | Screening method for the simultaneous determination of allantoin and uric acid from dried blood spots | |
| Larsen et al. | Blood values of juvenile northern elephant seals (Mirounga angustirostris) obtained using a portable clinical analyzer | |
| Son et al. | Cerebrospinal fluid lactate levels, brain lactate metabolism and neurologic outcome in patients with out-of-hospital cardiac arrest | |
| Brainina et al. | New electrochemical method of determining blood and blood fractions antioxidant activity | |
| Mittal et al. | Redox status of acute pancreatitis as measured by cyclic voltammetry: Initial rodent studies to assess disease severity | |
| Ahmad et al. | Observation on the changes in lactate dehydrogenase isoenzymes in post-burn patients: significance in relation to creatine kinase | |
| Önsüren et al. | Evaluation of Salivary Thiol/Disulfide Homeostasis and Oxidative Stress in Children with Severe Early Childhood Caries Using a Novel Method | |
| Wang | Lifestyle intervention in women with obesity and infertility: metabolic and nutritional characteristics and reproductive outcomes | |
| Singh et al. | A Comparative Study of Blood Glucose Level Measurement Between Glucometer and Semi Autoanalyser | |
| Altınsoy et al. | The Value of SCUBE-1 on Ischemia-Reperfusion Model in Diabetic Patients During Knee Replacement Surgery. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160527 |
|
| FZDE | Discontinued |
Effective date: 20190516 |
|
| FZDE | Discontinued |
Effective date: 20190516 |